Hetrombopag

DB16184InvestigationalSmall molecule

Hetrombopag is under investigation in clinical trial NCT03976882 (Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Malignancy.).

Mechanism: Pharmacologically active on Thrombopoietin receptor
Curator reviewed
Formula / weight: C₂₅H₂₂N₄O₅ · 458.474 g/mol (avg)
Also known as: Herombopag · Rafutrombopag
Code names: SHR-8735

Resolves to

Compound

UNII9WGT51BDDLCAS1257792-41-8

Structure

InChIKeyBDGGFTDRPHKXFC-QYQHSDTDSA-NSMILESCC1=NN(C(=O)\C1=N/NC1=C(O)C(=CC=C1)C1=CC=C(O1)C(O)=O)C1=CC=C2CCCCC2=C1

Targets

P40238MPL

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

60Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Hetrombopag, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account